-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VsOLmqccaT/3hPiLKpy39LCnavJJILmD5jwkUV0CW10iH/ZMA7XVTZZcaV9e7Z3s mEXHAT8m12HwdTKndCgy2g== 0000950134-08-002479.txt : 20080213 0000950134-08-002479.hdr.sgml : 20080213 20080213151844 ACCESSION NUMBER: 0000950134-08-002479 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080213 DATE AS OF CHANGE: 20080213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Targanta Therapeutics Corp. CENTRAL INDEX KEY: 0001398161 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203971077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-83189 FILM NUMBER: 08604170 BUSINESS ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 557-9020 MAIL ADDRESS: STREET 1: 222 THIRD AVENUE STREET 2: SUITE 2300 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: INTERMUNE INC CENTRAL INDEX KEY: 0001087432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943296648 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 3280 BAYSHORE STREET 2: BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415 466 2200 MAIL ADDRESS: STREET 1: 3280 BAYSHORE BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: INTERMUNE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000121 SC 13G 1 f38053sc13g.htm SCHEDULE 13G sc13g
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1932.
(Amendment No.      )*
Targanta Therapeutics Corporation
(Name of Issuer)
Common Stock, $.0001 par value
(Title of Class of Securities)


87612C100
(CUSIP Number)


December 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     o Rule 13d-1(b)
     o Rule 13d-1(c)
     þ Rule 13d-1(d)
*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 

Page 1 of 6 pages


 

                     
CUSIP No.
 
87612C100 
 

 

           
1   NAMES OF REPORTING PERSONS
I.R.S. Identification Nos. of above persons (entities only).

InterMune, Inc.
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)   o
  (b)   þ
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Delaware
       
  5   SOLE VOTING POWER
     
NUMBER OF   2,989,980
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   2,989,980
       
WITH: 8   SHARED DISPOSITIVE POWER
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  2,989,980
     
10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
   
  þ
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  14.20%
     
12   TYPE OF REPORTING PERSON
   
  CO

Page 2 of 6 pages

 


 

     
Item 1(a).
  Name of Issuer:
 
   
 
  Targanta Therapeutics Corporation
 
   
Item 1(b).
  Address of Issuer’s Principal Executive Offices:
 
   
 
  222 Third Street, Suite 2300, Cambridge, MA 02142-1122
 
   
Item 2(a).
  Name of Persons Filing:
 
   
 
  InterMune, Inc.
 
   
Item 2(b).
  Address of Principal Business Office, or if None, Residence:
 
   
 
  3280 Bayshore Boulevard, Brisbane, CA 94105
 
   
Item 2(c).
  Citizenship:
 
   
 
  InterMune is corporation organized under the laws of the State of Delware.
 
   
Item 2(d).
  Title of Class of Securities:
 
   
 
  Common Stock, $.0001 par value (the “Common Stock”)
 
   
Item 2(e).
  CUSIP Number:
 
   
 
  87612C100
Item 3.   If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
         
( a )
  o   Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
 
       
( b )
  o   Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
 
       
( c )
  o   Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
 
       
( d )
  o   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
 
       
( e )
  o   An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
 
       
( f )
  o   An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
Page 3 of 6 pages

 


 

         
( g )
  o   A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
 
       
( h )
  o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
       
( i )
  o   A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
       
( j )
  o   Group, in accordance with 240.13d-1(b)(1)(ii)(J).
Item 4.   Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
   
(a) Amount beneficially owned:
  2,989,980  
   
(b) Percent of class:
  14.20 %
   
(c) Number of shares as to which the person has:
     
   
(i) Sole power to vote or direct the vote:
  2,989,980  
   
(ii) Shared power to vote or to direct the vote:
  0  
   
(iii) Sole power to dispose or to direct the disposition of:
  2,989,980  
   
(iv) Shared power to dispose or to direct the disposition of:
  0  
Page 4 of 6 pages


 

     
Item 5.
  Ownership of Five Percent or Less of a Class.
 
   
 
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
 
   
Item 6.
  Ownership of More than Five Percent on Behalf of Another Person.
 
   
 
  Not Applicable
 
   
Item 7.
  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
 
   
 
  Not Applicable
 
   
Item 8.
  Identification and Classification of Members of the Group.
 
   
 
  Not Applicable
 
   
Item 9.
  Notice of Dissolution of Group.
 
   
 
  Not Applicable
 
   
Item 10.
  Certification.
 
   
 
  By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary couse of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaciton having such purposes or effect.
Page 5 of 6 pages

 


 

SIGNATURE
     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
         
 
  February 12, 2008    
 
       
 
  Date    
 
       
 
  /s/ John C. Hodgman    
 
       
 
  Signature    
 
       
 
       
 
  John C. Hodgman, Senior Vice    
 
  President, Finance and Chief    
 
  Financial Officer    
 
       
 
  Name/Title    
Page 6 of 6 pages

 

-----END PRIVACY-ENHANCED MESSAGE-----